Liraglutide

Most common during the first 2-4 weeks of therapy or dose escalation. Typically resolves within 1-2 weeks as the body adapts. Eating smaller, frequent meals and avoiding fatty or greasy foods may help. Taking the injection in the evening may reduce daytime nausea.

Occurs in approximately 5-10% of users, usually during initial titration. Typically mild and self-limiting. If persistent, contact a healthcare provider to discuss dose adjustment or timing changes.

Reported in 20-30% of users, often mild and transient. Related to slowed gastric emptying and increased colonic fluid. Usually resolves within 1-2 weeks. Increase fiber and fluid intake gradually.

Occurs in 15-25% of users, sometimes alternating with diarrhea. Increase water intake, dietary fiber, and physical activity. Over-the-counter stool softeners may help if needed.

This is an intended therapeutic effect. Ensure adequate protein and micronutrient intake despite reduced appetite to prevent malnutrition. Eat nutrient-dense foods in smaller portions.

Redness, itching, or mild swelling at the injection site occurs in 1-5% of users. Usually mild and self-resolving. Rotate injection sites to prevent lipodystrophy. Ensure proper injection technique and allow solution to reach room temperature before injection.

Reported in 5-10% of users, usually mild and transient. Often resolves within 1-2 weeks. Ensure adequate hydration and sleep.

May occur due to rapid weight loss or improved glycemic control, particularly in patients taking concurrent antidiabetic medications. Monitor blood glucose closely and adjust other medications as needed under medical supervision.

Risk is low when liraglutide is used as monotherapy due to glucose-dependent insulin secretion. Risk increases significantly when combined with insulin or sulfonylureas. Symptoms include tremor, sweating, palpitations, and confusion. Carry fast-acting carbohydrates and monitor blood glucose regularly if on concurrent insulin or sulfonylureas.

Rare but serious adverse event reported in <0.1% of users. Presents with severe upper abdominal pain, often radiating to the back, elevated pancreatic enzymes, and elevated lipase. Seek immediate medical attention if severe abdominal pain develops. Discontinue liraglutide and do not restart if acute pancreatitis is confirmed.

Rapid weight loss increases gallstone risk. Incidence is approximately 2-3% in clinical trials. Symptoms include right upper quadrant pain, nausea, and vomiting. Seek medical evaluation if these symptoms develop. Maintain gradual weight loss and adequate fat intake to reduce risk.

GLP-1 agonists caused C-cell hyperplasia and medullary thyroid carcinoma in rodent studies. Liraglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Monitor for thyroid nodules and elevated calcitonin in long-term use.

Can occur due to nausea, vomiting, or diarrhea, particularly in elderly patients or those with renal impairment. Maintain adequate fluid intake. Seek medical attention if signs of dehydration develop (dizziness, dark urine, extreme thirst).

Rapid improvement in glycemic control may transiently worsen diabetic retinopathy in patients with pre-existing retinopathy. This is not specific to liraglutide but occurs with rapid glucose normalization. Ophthalmologic monitoring is recommended, particularly in patients with baseline retinopathy.

Reported in 5-10% of users, often related to rapid weight loss or dietary changes. Ensure adequate caloric and protein intake, and maintain regular physical activity. Usually resolves within 2-4 weeks.